Mineralys Therapeutics In... (MLYS)
| Bid | 15.55 |
| Market Cap | 1.02B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -223.46M |
| EPS (ttm) | -3.66 |
| PE Ratio (ttm) | -4.44 |
| Forward PE | -2.56 |
| Analyst | Buy |
| Ask | 17.96 |
| Volume | 954,239 |
| Avg. Volume (20D) | 813,515 |
| Open | 17.08 |
| Previous Close | 16.87 |
| Day's Range | 16.19 - 17.34 |
| 52-Week Range | 8.24 - 18.38 |
| Beta | 1.51 |
About MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor...
Analyst Forecast
According to 3 analyst ratings, the average rating for MLYS stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 66.26% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Mineralys: Prospects Just Got Better With Successful Pivotal Data ReadoutsPrimary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data re...
1 month ago · seekingalpha.com
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call TranscriptMineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam ...
2 months ago · seekingalpha.com
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For HypertensionI believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 t...